Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,315.13 -722.96 (-1.11%) CMC Crypto 200
1,325.85 -34.47 (-2.53%)
TriSalus Life Sciences, Inc. (TLSI)
After hours:
- Business Wire
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
DENVER, June 03, 2024--TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that data from its Phase 1b PERIO-02 clinical trial was presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois.
- Business Wire
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
DENVER, May 24, 2024--TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today that it has commenced an exchange offer (the "Offer") and consent solicitation (the "Consent Solicitation") relating to its warrants (the "Warrants") identified in the Prospectus/Offer to Exchange (as defined below). The purpose of the
- Business Wire
TriSalus Reports Q1 2024 Financial Results and Business Update
DENVER, May 15, 2024--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update.
